With the research of driver mutations, targeted therapy for lung cancer has made a great progress. Compared with lung adenocarcinoma, treatment of squamous cell lung cancer (SCC) has been far behind. While targeted therapies have improved outcomes for patients with lung adenocarcinoma, such as EGFR-TKIs, EML4-ALK inhibitors, molecularly targeted drugs are poorly active for SCC. SCC currently lacks therapeutically exploitable genetic alterations. These observations emphasize the need for new driver mutations and "druggable" targets in SCC patients. Combining with the research in recent years, this review will discuss the research status in targeted therapy for SCC.
随着肺癌驱动基因研究的逐步深入，肺癌靶向治疗已取得较大进展。与肺腺癌相比，肺鳞癌的靶向治疗进展明显滞后。对肺腺癌临床疗效确切的靶向药物，如：表皮生长因子受体-酪氨酸激酶抑制剂（epidermal growth factor receptor-tyrosine kinase inhibitor, EGFR-TKI）、棘皮类微管相关样蛋白-4（echinodern microtubule-associated-protein-like 4, EML4）-间变型淋巴瘤激酶（anaplastic lymphoma kinase, ALK）融合基因抑制剂等，均对肺鳞癌疗效欠佳，目前肺鳞癌缺少有效的靶向治疗药物。因此，迫切需要对肺鳞癌的驱动基因和靶向治疗进行更深入的研究。本文将对肺鳞癌靶向治疗的研究现状作一综述。